platelet-derived growth factor receptor


Also found in: Wikipedia.

platelet-derived growth factor receptor

Any of a family of catalytic receptors with intracellular tyrosine kinase activity, which play key roles in regulating various biological processes such as embryonic development, angiogenesis, cell proliferation and differentiation. They also play a role in the pathogenesis of diseases, including cancer. Ligand binding to receptors triggers receptor dimerisation and transphosphorylation at specific tyrosine residues, activating intracellular kinase activity and initiating intracellular signalling through the MAPK, PI3K and PKC-gamma pathways.

PDGFRs are composed of three isoforms (a homodimer of PDGFRalpha, a homodimer of PDGFRbeta, and a heterodimer of PDGFRalpha and –beta) and four ligands (PDGF-A, -B, -C and -D).
References in periodicals archive ?
Immunohistochemical studies were strongly positive for CD34 and bcl-2, mildly positivefor phosphorylated protein kinase B and phosphorylated extracellular signal-regulated kinase 1/2, and negative for platelet-derived growth factor receptor alpha and p53.
Sorafenib inhibits KIT, the vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and BRAF kinases.
One common subtype is characterized by cells with increased signaling from a protein called platelet-derived growth factor receptor (PDGFR).
Imatinib is a tyrosine kinase receptor antagonist that inhibits the mutated tyrosine kinases such as Bcr-Abl, c-kit, and platelet-derived growth factor receptor (PDGFR) in some malignancies.
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.
The expression of CD44, cyclooxygenase 2, and platelet-derived growth factor receptor [alpha] (PDGFR-[alpha]) was evaluated as a potential prognostic factor for survival in patients with RCC.
Says Bonner, "Perhaps the most significant finding so far is that we defined the importance of two receptors--the platelet-derived growth factor receptor and the epidermal growth factor receptor--to the progression of lung fibrosis and showed that blocking these receptors with specific tyrosine kinase inhibitors reduced the fibrotic effect of vanadium pentoxide in rats.
Two important Sutent targets, vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) are expressed by many types of solid tumors and are thought to play a crucial role in angiogenesis, the process by which tumors acquire blood vessels, oxygen and nutrients needed for growth.
It targets growth factors, which have been implicated in pulmonary fibrosis C the vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), and platelet-derived growth factor receptor (PDGFR).
Two important SUTENT targets, vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR), are expressed by many types of solid tumors and are thought to play a crucial role in angiogenesis, the process by which tumors acquire blood vessels, oxygen and nutrients needed for growth.
It targets growth factors, which have been shown to be potentially involved in pulmonary fibrosis - the vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), and platelet-derived growth factor receptor (PDGFR).
Nintedanib* targets growth factor receptors, which have been shown to be potentially involved in the pathenogenesis of idiopathic pulmonary fibrosis, most importantly the vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR).

Full browser ?